COVID-19

COVID-19 Evidence Alerts
from McMaster PLUSTM

Current best evidence for clinical care (more info)

Register to receive email alerts

Search results

# Article
Higher quality Treatment Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2).
Sommer I, Ledinger D, Thaler K, et al.
Ann Intern Med
Reviewed: Sep 21, 2023
37722115
Higher quality Treatment Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
Wada T, Hibino M, Aono H, et al.
Front Med (Lausanne)
Reviewed: Jun 20, 2023
37283627
Higher quality Treatment Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, et al.
JAMA
Reviewed: Feb 28, 2023
36807465
Higher quality Primary Prevention Ivermectin role in the prevention of COVID-19: A systematic review and meta-analysis.
Hu GY, Liang CA, Lin PC, et al.
J Clin Pharmacol
Reviewed: Dec 19, 2022
36399336
Higher quality Treatment, Health promotion/primary prevention Ivermectin for preventing and treating COVID-19.
Popp M, Stegemann M, Metzendorf MI, et al.
Cochrane Database Syst Rev
Reviewed: Nov 8, 2022
34318930
Higher quality Treatment Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials.
Cheng Q, Zhao G, Chen J, et al.
Medicine (Baltimore)
Reviewed: Nov 1, 2022
36254081
Higher quality Treatment Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia.
Aref ZF, Bazeed SEES, Hassan MH, et al.
Infect Drug Resist
Reviewed: Oct 3, 2022
36164334
Higher quality Treatment Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Bramante CT, Huling JD, Tignanelli CJ, et al.
N Engl J Med
Reviewed: Sep 11, 2022
36070710
Higher quality Treatment Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype.
Marcolino MS, Meira KC, Guimaraes NS, et al.
BMC Infect Dis
Reviewed: Aug 11, 2022
35870876
Higher quality Treatment Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials.
Rezai MS, Ahangarkani F, Hill A, et al.
Front Med (Lausanne)
Reviewed: Jul 12, 2022
35783616
Higher quality Treatment Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
Mirahmadizadeh A, Semati A, Heiran A, et al.
Respirology
Reviewed: Jul 6, 2022
35738778
Higher quality Treatment Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schiesser S, et al.
Cochrane Database Syst Rev
Reviewed: Jun 29, 2022
35726131
Higher quality Treatment An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients.
Ravichandran R, Mohan SK, Sukumaran SK, et al.
Sci Rep
Reviewed: Apr 25, 2022
35440611
Higher quality Treatment Effect of Early Treatment with Ivermectin among Patients with Covid-19.
Reis G, Silva EASM, Silva DCM, et al.
N Engl J Med
Reviewed: Apr 12, 2022
35353979
Higher quality Treatment Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.
Lim SCL, Hor CP, Tay KH, et al.
JAMA Intern Med
Reviewed: Mar 3, 2022
35179551
Higher quality Treatment Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Zhang C, Jin H, Wen YF, et al.
Front Public Health
Reviewed: Oct 22, 2021
34650951
Higher quality Treatment Efficacy and safety of ivermectin for the treatment of COVID-19: A systematic review and meta-analysis.
Deng J, Zhou F, Ali S, et al.
QJM
Reviewed: Oct 15, 2021
34570241
Higher quality Primary Prevention Pharmacological interventions to prevent Covid-19 disease: A rapid review.
Cardwell K, O Murchu E, Byrne P, et al.
Rev Med Virol
Reviewed: Oct 14, 2021
34582072
Higher quality Treatment Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
Cheng Q, Chen J, Jia Q, et al.
Aging (Albany NY)
Reviewed: Sep 25, 2021
34531332
Higher quality Treatment Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Roman YM, Burela PA, Pasupuleti V, et al.
Clin Infect Dis
Reviewed: Aug 18, 2021
34181716
Higher quality Treatment Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
Vallejos J, Zoni R, Bangher M, et al.
BMC Infect Dis
Reviewed: Jul 21, 2021
34215210
Higher quality Treatment Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials.
Zein AFMZ, Sulistiyana CS, Raffaelo WM, et al.
Diabetes Metab Syndr
Reviewed: Jul 16, 2021
34237554
Higher quality Treatment Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.
Samaha AA, Mouawia H, Fawaz M, et al.
Viruses
Reviewed: Jul 14, 2021
34073401
Higher quality Treatment Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study.
Abd-Elsalam S, Noor RA, Badawi R, et al.
J Med Virol
Reviewed: Jul 1, 2021
34076901
Higher quality Treatment Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.
Mahmud R, Rahman MM, Alam I, et al.
J Int Med Res
Reviewed: May 22, 2021
33983065
Higher quality Primary Prevention Prophylaxis against covid-19: living systematic review and network meta-analysis.
Bartoszko JJ, Siemieniuk RAC, Kum E, et al.
BMJ
Reviewed: May 6, 2021
33903131
Higher quality Treatment Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
Bhowmick S, Dang A, Vallish BN, et al.
Drug Saf
Reviewed: Apr 26, 2021
33864232
Higher quality Treatment Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
Lopez-Medina E, Lopez P, Hurtado IC, et al.
JAMA
Reviewed: Mar 12, 2021
33662102
Higher quality Treatment Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis.
Padhy BM, Mohanty RR, Das S, et al.
J Pharm Pharm Sci
Reviewed: Feb 2, 2021
33227231
Under review Manuscript Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos.
Babalola OE, Bode CO, Ajayi AA, et al.
QJM
Reviewed: Feb 15, 2022
33599247
Does not meet our criteria Treatment Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Bramante CT, Buse JB, Liebovitz DM, et al.
Lancet Infect Dis
Reviewed: Jun 12, 2023
37302406
Does not meet our criteria Treatment An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand.
Sarojvisut P, Apisarnthanarak A, Jantarathaneewat K, et al.
Infect Chemother
Reviewed: Jan 6, 2023
36603821
Does not meet our criteria Treatment Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.
de la Rocha C, Cid-Lopez MA, Venegas-Lopez BI, et al.
BMC Infect Dis
Reviewed: Dec 22, 2022
36482326
Does not meet our criteria Treatment Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, et al.
JAMA
Reviewed: Nov 7, 2022
36269852
Does not meet our criteria Treatment Impact of SARS-CoV-2 vaccination and booster on COVID-19 symptom severity over time in the COVID-OUT trial.
Boulware DR, Murray TA, Proper JL, et al.
Clin Infect Dis
Reviewed: Sep 21, 2022
36124697
Does not meet our criteria Treatment A Randomized Controlled Trial of Combined Ivermectin and Zinc Sulfate versus Combined Hydroxychloroquine, Darunavir/Ritonavir, and Zinc Sulfate among Adult Patients with Asymptomatic or Mild Coronavirus-19 Infection.
Nimitvilai S, Suputtamongkol Y, Poolvivatchaikarn U, et al.
J Glob Infect Dis
Reviewed: Aug 23, 2022
35910820
Does not meet our criteria Treatment The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 - A double-blind, randomized placebo-controlled trial.
Biber A, Harmelin G, Lev D, et al.
Int J Infect Dis
Reviewed: Jul 11, 2022
35811080
Does not meet our criteria Treatment Is Ivermectin Effective in Treating COVID-19?
Yang S, Shen S, Hou N
Front Pharmacol
Reviewed: Jul 9, 2022
35800451
Does not meet our criteria Evidence Based Guideline Clinical Practice Guideline: Recommendations for the Outpatient Drug Treatment of Patients With COVID-19.
Kaduszkiewicz H, Kochen MM, Kluge S, et al.
Dtsch Arztebl Int
Reviewed: Jun 16, 2022
35506263
Does not meet our criteria Evidence Based Guideline Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges.
Nadeem S, Aamdani SS, Ayub B, et al.
Glob Health Epidemiol Genom
Reviewed: May 3, 2022
35492871
Does not meet our criteria Etiology Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis.
Bomze D, Sprecher E, Geller S
J Dermatol
Reviewed: Apr 28, 2022
35475524
Does not meet our criteria Review Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review.
Sharma SK, Bhatt P, Asdaq SMB, et al.
J Infect Public Health
Reviewed: Apr 25, 2022
35462191
Does not meet our criteria Evidence Based Guideline Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT).
Falavigna M, Belli KC, Barbosa AN, et al.
Braz J Infect Dis
Reviewed: Mar 28, 2022
35341739
Does not meet our criteria Review Ivermectin and the Integrity of Healthcare Evidence During COVID-19.
O'Mathuna DP
Front Public Health
Reviewed: Mar 18, 2022
35299698
Does not meet our criteria Review Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud.
Hill A, Mirchandani M, Ellis L, et al.
J Antimicrob Chemother
Reviewed: Feb 23, 2022
35190831
Does not meet our criteria Review Current status of therapeutic alternatives for COVID-19: A narrative review.
Aslan AT, Akova M
Infez Med
Reviewed: Feb 11, 2022
35146336
Does not meet our criteria Treatment High dose ivermectin for the early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof of concept clinical trial.
Buonfrate D, Chesini F, Martini D, et al.
Int J Antimicrob Agents
Reviewed: Feb 8, 2022
34999239
Does not meet our criteria Review Safety profile of COVID-19 drugs in a real clinical setting.
Chiu MN, Bhardwaj M, Sah SP
Eur J Clin Pharmacol
Reviewed: Jan 28, 2022
35088108
Does not meet our criteria Treatment The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness.
Zubair SM, Chaudhry MW, Zubairi ABS, et al.
Monaldi Arch Chest Dis
Reviewed: Jan 20, 2022
35044137
Does not meet our criteria Evidence Based Guideline ESCMID COVID-19 Living guidelines: drug treatment and clinical management.
Bartoletti M, Azap O, Barac A, et al.
Clin Microbiol Infect
Reviewed: Nov 26, 2021
34823008
Does not meet our criteria Review Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Cruciani M, Pati I, Masiello F, et al.
Diagnostics (Basel)
Reviewed: Sep 28, 2021
34573986
Does not meet our criteria Primary Prevention Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study.
Morgenstern J, Redondo JN, Olavarria A, et al.
Cureus
Reviewed: Sep 14, 2021
34513523
Does not meet our criteria Primary Prevention Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers.
Behera P, Patro BK, Padhy BM, et al.
Cureus
Reviewed: Sep 14, 2021
34513470
Does not meet our criteria Review Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature.
Chaudhry MW, Zubair SM, Zubairi ABS, et al.
Adv Respir Med
Reviewed: Sep 9, 2021
34494244
Does not meet our criteria Treatment Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response.
Pedroso C, Vaz S, Netto EM, et al.
Braz J Infect Dis
Reviewed: Aug 16, 2021
34390646
Does not meet our criteria Review Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review.
Bestetti RB, Furlan-Daniel R, Silva VMR
Int J Environ Res Public Health
Reviewed: Jul 20, 2021
34281149
Does not meet our criteria Treatment Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
Ravikirti, Roy R, Pattadar C, et al.
J Pharm Pharm Sci
Reviewed: Jul 16, 2021
34265236
Does not meet our criteria Treatment Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients.
Cadegiani FA, Goren A, Wambier CG, et al.
New Microbes New Infect
Reviewed: Jul 12, 2021
34249367
Does not meet our criteria Evidence Based Guideline Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021).
Malin JJ, Spinner CD, Janssens U, et al.
Infection
Reviewed: Jul 7, 2021
34228347
Does not meet our criteria Review The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review.
Frediansyah A
Clin Epidemiol Glob Health
Reviewed: Jul 6, 2021
34222718
Does not meet our criteria Treatment Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial.
Krolewiecki A, Lifschitz A, Moragas M, et al.
EClinicalMedicine
Reviewed: Jul 2, 2021
34189446
Does not meet our criteria Treatment Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
Okumus N, Demirturk N, Cetinkaya RA, et al.
BMC Infect Dis
Reviewed: May 6, 2021
33947344
Does not meet our criteria Evidence Based Guideline Guidelines for clinical management of SARS-CoV-2 infection.
Garcia-Alvarez JL, Garcia-Vigil JL
Gac Med Mex
Reviewed: Apr 28, 2021
33877121
Does not meet our criteria Treatment Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial.
Seet RCS, Quek AML, Ooi DSQ, et al.
Int J Infect Dis
Reviewed: Apr 20, 2021
33864917
Does not meet our criteria Review Drugs intervention study in COVID-19 management.
Taher M, Tik N, Susanti D
Drug Metab Pers Ther
Reviewed: Apr 8, 2021
33818031
Does not meet our criteria Treatment Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.
Elalfy H, Besheer T, El-Mesery A, et al.
J Med Virol
Reviewed: Feb 17, 2021
33590901
Does not meet our criteria Treatment Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study.
Behera P, Patro BK, Singh AK, et al.
PLoS One
Reviewed: Feb 17, 2021
33592050
Does not meet our criteria Treatment The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
Chaccour C, Casellas A, Blanco-Di Matteo A, et al.
EClinicalMedicine
Reviewed: Jan 27, 2021
33495752
Does not meet our criteria Review A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity.
Little C, Cosetti MK
Laryngoscope
Reviewed: Jan 26, 2021
33491234
Does not meet our criteria Review From Hydroxychloroquine to Ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Rakedzon S, Neuberger A, Domb AJ, et al.
J Travel Med
Reviewed: Jan 23, 2021
33480414
Does not meet our criteria Review Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
Kim MS, An MH, Kim WJ, et al.
PLoS Med
Reviewed: Dec 31, 2020
33378357
Does not meet our criteria Treatment A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Ahmed S, Karim MM, Ross AG, et al.
Int J Infect Dis
Reviewed: Dec 21, 2020
33278625
Does not meet our criteria Treatment Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.
Camprubi D, Almuedo-Riera A, Marti-Soler H, et al.
PLoS One
Reviewed: Nov 13, 2020
33175880
Does not meet our criteria Treatment Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study).
Rajter JC, Sherman MS, Fatteh N, et al.
Chest
Reviewed: Oct 22, 2020
33065103
Not a category we appraise Primary Prevention Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis.
Zhou G, Verweij S, Bijlsma MJ, et al.
BMJ Open Respir Res
Reviewed: Aug 30, 2023
37640510
Not a category we appraise Review Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview.
Mohseni M, Ameri H, Arab-Zozani M
Front Med (Lausanne)
Reviewed: Oct 7, 2022
36203750
Not a category we appraise Mucormycosis, one month after recovery from COVID-19: A case report.
Alian S, Ahangarkani F, Boskabadi SJ, et al.
Ann Med Surg (Lond)
Reviewed: Jun 13, 2022
35693105
Not a category we appraise COVID-19: Implications Regarding the Properties and Behaviors of the Coronavirus Disease.
Chen MH, Tulp OL, Einstein GP
FASEB J
Reviewed: May 16, 2022
35557428
Not a category we appraise Retraction to: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection.
Hill A, Garratt A, Levi J, et al.
Open Forum Infect Dis
Reviewed: Feb 11, 2022
35146053
Not a category we appraise Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud.
Hill A, Mirchandani M, Pilkington V
Open Forum Infect Dis
Reviewed: Jan 25, 2022
35071686
Not a category we appraise Review Self-medication practices to prevent or manage COVID-19: A systematic review.
Quincho-Lopez A, Benites-Ibarra CA, Hilario-Gomez MM, et al.
PLoS One
Reviewed: Nov 3, 2021
34727126
Not a category we appraise Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]".
Krolewiecki A, Lifschitz A, Moragas M, et al.
EClinicalMedicine
Reviewed: Sep 1, 2021
34462733
Not a category we appraise Erratum: Expression of Concern: "Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection".
Hill A, Garratt A, Levi J, et al.
Open Forum Infect Dis
Reviewed: Aug 20, 2021
34410284